Skip to Main Content

Author Details

Louis Vermeulen
Oncode Institute
2006
129
46
PMIDPaper TitleJournal TitlePublished Year
36069222Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.Int J Cancer2023
37405857Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.J Natl Cancer Inst2023
37364735Caffeine Limits Expansion of Apc-Deficient Clones in the Intestine by NOTUM Inhibition.Cell Mol Gastroenterol Hepatol2023
37030079Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis.Eur J Cancer2023
36869386Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.J Exp Clin Cancer Res2023
36906044Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer.Gastroenterology2023
36826817Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas: A Systematic Review and Meta-analysis.JAMA Netw Open2023
36564280Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.Clin Colorectal Cancer2023
36700339The molecular biology of peritoneal metastatic disease.EMBO Mol Med2023
36175766Cell competition in development, homeostasis and cancer.Nat Rev Mol Cell Biol2023
34077519Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.J Natl Cancer Inst2022
35470895Copy-number intratumor heterogeneity as high-risk feature of stage II colon cancer<sup>â¿ </sup>.J Pathol2022
35630206The Effect of Dynamic, In Vivo-like Oxaliplatin on HCT116 Spheroids in a Cancer-on-Chip Model Is Representative of the Response in Xenografts.Micromachines (Basel)2022
35413826Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.BMC Cancer2022
36591246Behavioral factors to modulate immunotherapy efficacy in cancer.Front Immunol2022
35962368The CHAMP-study: the CHemopreventive effect of lithium in familial AdenoMatous Polyposis; study protocol of a phase II trial.BMC Gastroenterol2022
35864159Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.Br J Cancer2022
35927254Molecular characterization of colorectal cancer related peritoneal metastatic disease.Nat Commun2022
36321561Intestinal Apc-inactivation induces HSP25 dependency.EMBO Mol Med2022
35043009Primary tumour immune response and lymph node yields in colon cancer.Br J Cancer2022
35153158Intestinal stem cell dynamics in homeostasis and cancer.Trends Cancer2022
35298091Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.Mol Oncol2022
33414546Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target.Nat Genet2021
33900400Predictors of 30-Day Mortality Among Dutch Patients Undergoing Colorectal Cancer Surgery, 2011-2016.JAMA Netw Open2021
33673003AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition.Cancers (Basel)2021
33773183Mimicking and surpassing the xenograft model with cancer-on-chip technology.EBioMedicine2021
34977689Intestinal organoid co-culture protocol to study cell competition <i>in vitro</i>.STAR Protoc2021
34616875Predicting survival of cancer patients by chromosomal copy number heterogeneity.Mol Cell Oncol2021
34424199Integrated single-cell analysis unveils diverging immune features of COVID-19, influenza, and other community-acquired pneumonia.Elife2021
34686335Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer.Cell Rep2021
34079128Apc-mutant cells act as supercompetitors in intestinal tumour initiation.Nature2021
34045449Chromosomal copy number heterogeneity predicts survival rates across cancers.Nat Commun2021
34219052High-Fat Diet Impacts on Tumor Development in the Gut.Trends Cancer2021
34068407Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression.Cancers (Basel)2021
34209288Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer.Cancers (Basel)2021
34358441Continuous clonal labeling reveals uniform progenitor potential in the adult exocrine pancreas.Cell Stem Cell2021
34284100The recurring features of molecular subtypes in distinct gastrointestinal malignancies-A systematic review.Crit Rev Oncol Hematol2021
34331598Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.Med Oncol2021
34253874Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.Br J Cancer2021
34162659Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers.Cancer Epidemiol Biomarkers Prev2021
33191154Confusion on Cell Fusion.Cell Mol Gastroenterol Hepatol2021
33189690Rebuttal to: Digesting the Importance of Cell Fusion in the Intestine.Cell Mol Gastroenterol Hepatol2021
32401426Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.J Pathol Clin Res2020
31941932Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems.Sci Rep2020
33352769Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer.Cancers (Basel)2020
33292279Intestinal region-specific Wnt signalling profiles reveal interrelation between cell identity and oncogenic pathway activity in cancer development.Cancer Cell Int2020
32581367Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.Mod Pathol2020
32504005A mouse model for peritoneal metastases of colorectal origin recapitulates patient heterogeneity.Lab Invest2020
32523045A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.Nat Commun2020
30478449Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.Oncogene2019
  • 1 - 50 of 129

Recommended Authors

Walid K Chatila
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 0
Daniela Hirsch
Institute of Pathology, University Medical Center Mannheim, University of Heidelberg
Career Start Year 2012
Number of shared co-authors 1
Amy M B McCorry
Queen's University Belfast
Career Start Year 2012
Number of shared co-authors 0
Faiyaz Notta
2Ontario Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 1
Ruby Yun-Ju Huang
National Taiwan University College of Medicine
Career Start Year 2008
Number of shared co-authors 0
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 3
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 5
Eduardo Vilar
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 1
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 1
Kurt W Fisher
University of Nebraska Medical Center
Career Start Year 2004
Number of shared co-authors 1
Christina Curtis
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 9
Ken S Lau
Vanderbilt University School of Medicine
Career Start Year 2003
Number of shared co-authors 0
Susan L Woods
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 0
Itzhak Avital
Goldman School of Medicine, Ben Gurion University
Career Start Year 2001
Number of shared co-authors 0
Andrea Viale
The University of Texas MD Anderson Cancer Center
Career Start Year 2001
Number of shared co-authors 4
Daniel L Worthley
South Australian Health and Medical Research Institute
Career Start Year 2001
Number of shared co-authors 0
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 2000
Number of shared co-authors 8
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 4
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 4
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
William M Grady
. Fred Hutchinson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 8
John M Mariadason
Olivia Newton-John Cancer Research Institute
Career Start Year 1996
Number of shared co-authors 1
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 8
Nabeel Bardeesy
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 1
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 7
Laurie Ailles
University of Toronto
Career Start Year 1991
Number of shared co-authors 0
Melissa H Wong
Oregon Health & Science University
Career Start Year 1988
Number of shared co-authors 3
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 8

Collaborators

Jan Paul Medema
Oncode Institute
Co-authored papers 50
Jan Koster
Amsterdam University Medical Centers location AMC
Co-authored papers 8
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 6
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Co-authored papers 5
Gerrit A Meijer
The Netherlands Cancer Institute
Co-authored papers 5
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 5
Clara C Elbers
Co-authored papers 4
Remond J A Fijneman
The Netherlands Cancer Institute
Co-authored papers 4
Andrea Sottoriva
The Institute of Cancer Research, UK Computational Biology Research Centre
Co-authored papers 4
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 4
Tijana Borovski
Cancer Center, University Medical Center Utrecht
Co-authored papers 4
Hanneke W M van Laarhoven
Cancer Center Amsterdam
Co-authored papers 4
Simon Tavar??
Irving Institute for Cancer Dynamics, Columbia University
Co-authored papers 3
Justin Guinney
University of Washington
Co-authored papers 3
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 3
Mauro Delorenzi
Co-authored papers 2
Lorenzo Memeo
Co-authored papers 2
Peter M A Sloot
Institute for Advanced Study, University of Amsterdam.
Co-authored papers 2
Joe W Gray
Oregon Health and Science University
Co-authored papers 2
William H Bisson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
David A Largaespada
University of Minnesota
Co-authored papers 2
Brendon P Scicluna
Mater Dei Hospital, University of Malta
Co-authored papers 2
Fahd Al-Mulla
Dasman Diabetes Institute
Co-authored papers 2
Joost J C Verhoeff
University Medical Center Utrecht
Co-authored papers 2
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 2
Ted Laderas
Oregon Health & Science University
Co-authored papers 1
Roel G W Verhaak
Yale School of Medicine
Co-authored papers 1
Oscar M Rueda
University of Cambridge
Co-authored papers 1
Thomas Wurdinger
Co-authored papers 1
Release 1.2